Atorvastatin: Difference between revisions
Gerald Chi (talk | contribs) |
Gerald Chi (talk | contribs) |
||
| Line 33: | Line 33: | ||
==Mechanism of Action== | ==Mechanism of Action== | ||
Atorvastatin is a selective, competitive inhibitor of [[HMG-CoA reductase]], the rate-limiting enzyme that converts 3-hydroxy-3-methylglutaryl-coenzyme A to [[mevalonate]], a precursor of [[cholesterol]]. | |||
In animal models, atorvastatin lowers plasma cholesterol and [[lipoprotein]] levels by inhibiting [[HMG-CoA reductase]] and [[cholesterol]] synthesis in the liver and by increasing the number of hepatic [[LDL receptor]]s on the cell surface to enhance uptake and catabolism of LDL; atorvastatin also reduces [[LDL]] production and the number of [[LDL]] particles. Atorvastatin reduces [[LDL]]-C in some patients with homozygous [[familial hypercholesterolemia]] (FH), a population that rarely responds to other lipid-lowering medication(s). | |||
Atorvastatin reduces total-C, [[LDL]]-C, and [[apo B]] in patients with homozygous and heterozygous FH, nonfamilial forms of [[hypercholesterolemia]], and mixed [[dyslipidemia]]. | |||
Atorvastatin also reduces [[VLDL]]-C and [[TG]] and produces variable increases in [[HDL]]-C and apolipoprotein A-1. | |||
Atorvastatin reduces total-C, [[LDL]]-C, [[VLDL]]-C, [[apo B]], [[TG]], and non-[[HDL]]-C, and increases [[HDL]]-C in patients with isolated [[hypertriglyceridemia]]. | |||
Atorvastatin reduces intermediate density [[lipoprotein]] [[cholesterol]] ([[IDL]]-C) in patients with [[dysbetalipoproteinemia]].<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = LIPITOR (ATORVASTATIN CALCIUM) TABLET, FILM COATED [PARKE-DAVIS DIV OF PFIZER INC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c6e131fe-e7df-4876-83f7-9156fc4e8228#nlm34089-3 | publisher = | date = | accessdate = }}</ref> | |||
==References== | ==References== | ||
{{Reflist}} | {{Reflist}} | ||
Revision as of 20:11, 30 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Pratik Bahekar, MBBS [2]
For patient information, click here.
Overview
Atorvastatin is a member of the drug class known as statins, used for lowering blood cholesterol. It also stabilizes plaque and prevents strokes through anti-inflammation and other mechanisms. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body.
Category
Lipid-Lowering Agents, Statins
US Brand Names
Lipitor®
FDA Package Insert
Indications and Usage | Dosage and Administration | Contraindications | Warnings and Precautions | Adverse Reactions | Overdosage | Description | Clinical Pharmacology | Clinical Studies | How Supplied/Storage and Handling | Labels and Packages
Mechanism of Action
Atorvastatin is a selective, competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme that converts 3-hydroxy-3-methylglutaryl-coenzyme A to mevalonate, a precursor of cholesterol.
In animal models, atorvastatin lowers plasma cholesterol and lipoprotein levels by inhibiting HMG-CoA reductase and cholesterol synthesis in the liver and by increasing the number of hepatic LDL receptors on the cell surface to enhance uptake and catabolism of LDL; atorvastatin also reduces LDL production and the number of LDL particles. Atorvastatin reduces LDL-C in some patients with homozygous familial hypercholesterolemia (FH), a population that rarely responds to other lipid-lowering medication(s).
Atorvastatin reduces total-C, LDL-C, and apo B in patients with homozygous and heterozygous FH, nonfamilial forms of hypercholesterolemia, and mixed dyslipidemia.
Atorvastatin also reduces VLDL-C and TG and produces variable increases in HDL-C and apolipoprotein A-1.
Atorvastatin reduces total-C, LDL-C, VLDL-C, apo B, TG, and non-HDL-C, and increases HDL-C in patients with isolated hypertriglyceridemia.
Atorvastatin reduces intermediate density lipoprotein cholesterol (IDL-C) in patients with dysbetalipoproteinemia.[1]